David Omalley, MD
Gynecologic Oncology · Hilliard, OHNPI 1609819424
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $452,818 of the $649,547 with a category attached, or 69.7%. It is spread thinly across 36 manufacturers, the largest accounting for just 19.3%. 2025 is the largest year on record at $161,764, 2.5 times the $65,038 reported in 2019. Among gynecologic oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $1344.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$125K
- Eisai Inc.$73K
- AstraZeneca$72K
- AbbVie$58K
- GSK$54K
- Daiichi Sankyo Inc.$48K
- plus $219K from 30 others
Across 733 payments — averaging $13,825 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3.7M
- Merck$1.5M
- Eli Lilly$1.3M
- Clovis Oncology, Inc.$599K
- Seagen Inc.$438K
- Genentech, Inc.$426K
- plus $2.1M from 15 others
What the payments were for
- Consulting fees$452,81870%
- Speaking & faculty fees$94,62015%
- Travel & lodging$88,80314%
- Food & beverage$13,2702%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 71 | $125,065 |
| Eisai Inc. | 46 | $73,376 |
| AstraZeneca | 79 | $72,331 |
| AbbVie | 39 | $57,765 |
| GSK | 28 | $53,819 |
| Daiichi Sankyo Inc. | 23 | $48,013 |
| Regeneron | 21 | $25,516 |
| Genmab U.S., Inc. | 15 | $22,068 |
| Seagen Inc. | 22 | $20,054 |
| Astrazeneca UK Limited | 14 | $19,484 |
| Novocure Inc. | 17 | $18,393 |
| Corcept Therapeutics | 13 | $12,876 |
| Roche Diagnostics Corporation | 7 | $11,448 |
| Pfizer | 3 | $11,116 |
| Clovis Oncology, Inc. | 30 | $9,754 |
| Aadi Bioscience, Inc. | 9 | $8,191 |
| Novocure GmbH | 4 | $7,692 |
| Beigene USA, Inc. | 2 | $7,150 |
| Biontech SE | 4 | $5,014 |
| Immunogen, Inc. | 6 | $4,692 |
| Incyte Corporation | 3 | $4,025 |
| Beone Medicines USA, Inc. | 3 | $4,000 |
| Eli Lilly | 2 | $3,825 |
| Immunocore Limited | 2 | $3,685 |
| Novartis | 2 | $3,468 |
| Day One Biopharmaceuticals | 1 | $3,400 |
| Genentech USA, Inc. | 4 | $2,897 |
| Genentech, Inc. | 2 | $2,819 |
| Novartis Pharma AG | 1 | $2,460 |
| Jazz Pharmaceuticals Inc. | 1 | $1,800 |
| Myriad Genetic Laboratories, Inc. | 2 | $1,578 |
| Tesaro, Inc. | 2 | $1,417 |
| Pharmaand GmbH | 2 | $224 |
| Karyopharm Therapeutics Inc. | 1 | $85 |
| Mindray DS USA, Inc. | 1 | $29 |
| Syndax Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$72,561
- LYNPARZA$62,145
- TIVDAK$22,830
- Elahere$17,389
- JEMPERLI$11,800
- KEYTRUDA$10,363
- ZEJULA$9,398
- Oncology$8,972
- Rubraca$8,938
- EPKINLY$8,132
- Enhertu$7,592
- FYARRO$7,241
- Korlym$6,639
- CINtec PLUS Cytology$6,600
- Optune$4,800
- KIMMTRAK$3,600
- BENCHMARK SPECIAL STAINS WASH II$3,500
- Avastin$2,785
- TECENTRIQ$2,640
- PRM_PROMACTA_ONCOLOGY$2,460
How this compares
$649,547 in reported general payments places this provider in the 95th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 13 | $241,580 |
| Ibuprofen | 12 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $53,819 | $241,58013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 gynecologic oncology providers in Ohio.
Other gynecologic oncology in Hilliard
- Floortje BackesHilliard$181K
- Casey CosgroveHilliard$30K
- Robert NeffHilliard$15K
- Larry CopelandHilliard$12K
- Jeffrey FowlerHilliard$720
- Paulina HaightHilliard$117
- Thomas HerzogCincinnati$585K
- Adam WalterSylvania$137K
- Amanda JacksonCincinnati$92K
- Amelia JerniganCleveland$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.